Drugs / GP2 peptide
last change Mar 2017 re-read 2 minutes ago

GP2 peptide

Peptide

Developed for
breast cancer
Investigated by
Cancer Insight, LLC · Norwell, Inc. · NuGenerex Immuno-Oncology · San Antonio Military Medical Center

Trials 2 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03014076 Jan 2008 → Jan 2016 breast cancer Cancer Insight, LLC Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00524277 Jan 2007 → Dec 2014 breast cancer San Antonio Military Medical Center Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GP2 peptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00524277
1

NCT03014076

Modality Peptide “GP2 peptide vaccine” NCT03014076